Evidence map›Paper›PMID 40576528›Full record

ArticleJournal of Parkinson's disease2025

Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease.

Mathilde Boussac, Florent Faggianelli, Estelle Harroch, Alexandre Eusebio, Margherita Fabbri, Fabienne Ory-Magne, Emeline Descamps, Olivier Rascol, Chloé Laurencin, Ana-Raquel Marques and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Mathilde BoussacToulouse NeuroImaging Center (ToNIC), Inserm UMR1214, University of Toulouse III, UPS, Toulouse, France.ORCID 0000-0002-3532-6743
Florent FaggianelliAix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.ORCID 0000-0003-1007-7522
Estelle HarrochDepartment of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse, NS-PARK/FCRIN Network, France.
Alexandre EusebioAix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.
Margherita FabbriToulouse NeuroImaging Center (ToNIC), Inserm UMR1214, University of Toulouse III, UPS, Toulouse, France.
Fabienne Ory-MagneToulouse NeuroImaging Center (ToNIC), Inserm UMR1214, University of Toulouse III, UPS, Toulouse, France.ORCID 0000-0001-6179-4500
Emeline DescampsToulouse NeuroImaging Center (ToNIC), Inserm UMR1214, University of Toulouse III, UPS, Toulouse, France.ORCID 0000-0002-0675-2989
Olivier RascolToulouse NeuroImaging Center (ToNIC), Inserm UMR1214, University of Toulouse III, UPS, Toulouse, France.
Chloé LaurencinService de Neurologie C, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Lyon, France.
Ana-Raquel MarquesDepartment of Neurology, CHU Clermont-Ferrand, Université Clermont-Auvergne, IGCNC, Institut Pascal, Clermont-Ferrand, NS-Park/F-CRIN Network, France.ORCID 0000-0003-2428-4899
Mathieu AnheimDépartement de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg and NS-Park/FCRIN Network Strasbourg, France.
Bruno GiordanaService Universitaire de Psychiatrie, Hôpital Pasteur 1, CHU de Nice, Nice, France.ORCID 0000-0001-7293-6607
Lucie HopesNeurology Department, Nancy University Hospital, Nancy, France; NS-Park French Network.ORCID 0009-0008-2982-0658
Caroline MoreauDepartment of Medical Pharmacology, Neurology and Movement Disorders Department, Referent center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN Network, France.
Anne-Sophie RollandDepartment of Medical Pharmacology, Neurology and Movement Disorders Department, Referent center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN Network, France.ORCID 0000-0001-7888-9354
David DevosDepartment of Medical Pharmacology, Neurology and Movement Disorders Department, Referent center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille, NS-PARK/FCRIN Network, France.ORCID 0000-0002-2417-799X
David MaltêteDepartment of Neurology, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France.
Solène AnsquerService de neurologie, CHU POITIERS; CIC INSERM 1402, CHU POITIERS, Poitiers, France.
Elodie HainqueDépartement de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, F-75013, Paris, France.
Sophie DrapierCHU Pontchaillou, service de neurologie, CiC Inserm 1414, Rennes, France.ORCID 0000-0002-5376-0869
Jean-Philippe BrandelDepartment of Neurology, Hospital Fondation Rothschild, Paris, France.
Tiphaine RouaudDepartment of Neurology, CHU de Nantes, NS-Park/F-Crin network, Nantes, France.ORCID 0000-0003-2885-7906
Dominique GuehlService de Neurophysiologie Clinique de l'enfant et de l'adulte, Pôle des Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.ORCID 0000-0003-0388-6727
Bechir JarrayaPôle Neurosciences, Foch Hospital, Suresnes; Université Paris-Saclay, UVSQ, INSERM U992, CEA Paris-Saclay, Neurospin, France.ORCID 0000-0003-0878-763X
Mélissa TirService de Neurologie, Centre Expert de la maladie de Parkinson, CHU Amiens, Amiens, France.
Tatiana WitjasAix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.
Jean-Philippe AzulayAix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.ORCID 0000-0001-6624-3329
Christine Brefel-CourbonToulouse NeuroImaging Center (ToNIC), Inserm UMR1214, University of Toulouse III, UPS, Toulouse, France.ORCID 0009-0002-7262-2338
PREDISTIM study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundParkinson's disease (PD) patients on dopaminergic drugs may experience non-motor fluctuations (NMFs) which are often heterogeneous and respond variably to treatments.ObjectiveWe evaluated if personality was associated to NMFs and could modulate the NMFs responsiveness to dopaminergic medication and deep brain stimulation of the sub-thalamic nucleus (STN-DBS).MethodsFrom the PREDISTIM cohort, personality dimensions of 235 PD patients were assessed by the Temperament and Character Inventory (TCI) before STN-DBS (V0). NMFs were evaluated using the NMFs Severity Scale at V0 and one year after STN-DBS (V1). Linear regression models were performed between TCI dimensions and NMFs at V0; and logistic regression models were done between TCI dimensions and 1) groups of dopa-sensitive patients (responders to ON medication at V0) versus non-dopa-sensitive ones, and 2) responders versus non-responders to STN-DBS at V1. Odds ratios (OR) were also calculated.ResultsSignificant associations were found between two TCI personality dimensions ("Harm Avoidance" and "Self-Directedness") and severity of NMFs in OFF medication at V0: PD patients with higher Harm Avoidance and lower Self-Directedness scores having more NMFs. TCI personality dimensions were not associated with the dopa-sensitivity while Novelty Seeking was significantly associated with the STN-DBS-responder group for the psychiatric (OR = 1.09 [1.02-1.17]) and for the dysautonomic NMFs (OR = 1.11 [1.04-1.18]).ConclusionsCertain personality dimensions (Harm Avoidance and Self-Directedness) are associated with NMFs severity at baseline, and PD patients with high Novelty Seeking seem to be better candidates for NMFs improvement after STN-DBS.

Indexed as

Deep Brain StimulationParkinson DiseasePersonalityAgedAntiparkinson AgentsFemaleHumansMaleMiddle AgedSeverity of Illness IndexSubthalamic NucleusAntiparkinson AgentsNon-motor fluctuationsParkinson's diseasePersonalityTemperament and Character Inventory

Identifiers

PMID40576528
PMCPMC13347507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.